Founded with the mission to revolutionize cell therapy and vaccine development, CellChorus leverages artificial intelligence to analyze thousands of microscopy videos in parallel. This innovative approach enables the evaluation of immune cell behavior over time, helping customers discover, develop, manufacture, and deliver therapies more efficiently and cost-effectively. Their core product, the TIMING™ platform, quantifies the spatiotemporal performance of individual cells, providing critical insights for top biopharma companies and emerging biotech firms.
Notable figures affiliated with CellChorus include leading scientists and industry experts who contribute to the company's cutting-edge research and development. The company has secured investments from prominent venture capital firms and has achieved significant milestones in accelerating therapeutic development. By enabling a deeper understanding of immune cell performance, CellChorus has made a substantial impact on the biopharma industry, enhancing the success rates of novel therapies and reducing time-to-market.
